Table 1.
Characteristics of adults with VAERS reports following COVID-19 vaccination (N = 8,976).
| Characteristics | N | % |
|---|---|---|
| Age | ||
| 18–64 years | 8,207 | 91.4 |
| 65+ years | 769 | 8.6 |
| Gender | ||
| Female | 7,033 | 78.6 |
| Male | 1,914 | 21.4 |
| Onset interval | ||
| 0 day | 5,353 | 61.0 |
| 1–7 days | 3,145 | 35.9 |
| 8–14 days | 179 | 2.0 |
| ≥15 days | 93 | 1.1 |
| Dose | ||
| 1st dose | 7,300 | 95.9 |
| 2nd doses | 314 | 4.1 |
| Manufacture | ||
| Pfizer-BioNTech | 6,964 | 77.6 |
| Moderna | 2,009 | 22.4 |
| Series reports | 1,155 | 11.8 |
| Death | 266 | 2.7 |
| Life-threatening illness | 265 | 2.7 |
| Permanent Disability | 101 | 1.0 |
| Hospitalizations | 698 | 7.1 |
| Office visits | 1,194 | 12.2 |
| ER visits | 1,998 | 20.4 |
| Top 10 AEs | ||
| Headache | 1,977 | 22.0 |
| Fatigue | 1,464 | 16.3 |
| Dizziness | 1,370 | 15.3 |
| Chills | 1,320 | 14.7 |
| Pyrexia | 1,307 | 14.6 |
| Nausea | 1,305 | 14.5 |
| Pain | 1,239 | 13.8 |
| Injection site pain | 904 | 10.1 |
| Pain in extremity | 783 | 8.7 |
| Dyspnoea | 663 | 7.4 |
ER, Emergency room; AE, Adverse event.